Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic
sequencing in individuals with this condition might constitute a non-invasive approach for …

Abstract Proton Pump Inhibitors are used widely to manage many gastric acid-related
conditions such as gastroesophageal disease, gastritis, esophagitis, Barrett's esophagus …

Background & Aims To identify gut and oral metagenomic signatures that accurately predict
pancreatic ductal carcinoma (PDAC) and to validate these signatures in independent …

Aims The aim was to perform an umbrella review to summarise the existing evidence on
proton‐pump inhibitor (PPI) use and adverse outcomes and to grade the certainty of …

Pancreatic cancer is becoming an increasing healthcare concern. Though it is a 14th most
common cancer worldwide, its incidence is steadily rising. Results of currently available …

Simple Summary Proton pump inhibitors are commonly prescribed medications for
gastrointestinal disorders, which bring gastric acid down to normal levels. However, the …

Background For the past two decades, dispute on whether proton pump inhibitor (PPI) leads
to digestive tract cancer remains, and emerging studies in recent years still demonstrate …

Objectives: Increasing evidence suggested that proton pump inhibitors (PPIs) use might
affect the development of cancers, but previous conclusions remain controversial. Therefore …

Background: Proton pump inhibitors (PPIs) are commonly prescribed long-acting drugs used
to treat acid reflux, gastroesophageal reflux disease (GERD), and peptic ulcers. Recently …

Adverse drug reactions (ADRs) affecting the pancreas are a heterogeneous group of side
effects that cause damage to pancreatic cells. Various mechanisms such as …